Search
Warfarin
go.drugbank.com/drugs/DB00682ApprovedInvestigationalAlthough originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. … Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration.
Categories: Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexZanidatamab
go.drugbank.com/drugs/DB15471ApprovedInvestigationalZanidatamab is a bispecific antibody that binds two non-overlapping sites of HER2 (ERBB2). … [A264718] In November 2024, the FDA granted an accelerated approval for zanidatamab for use in previously treated unresectable or metastatic HER2-positive biliary tract cancers.[L51908,L51903]
Nitazoxanide
go.drugbank.com/drugs/DB00507ApprovedInvestigationalVet approvedNitazoxanide is a first-line, standard treatment for illness caused by C. parvum or G. lamblia infection in healthy (not immunosuppressed) adults and children and may also be considered in the treatment … microaerophilic bacteria, in addition to viruses.
Products: N/a, XINPA 2 % POLVO PARA RECONSTITUIR A SUSPENSIÓN ORALMedrogestone
go.drugbank.com/drugs/DB09124ApprovedWithdrawnMedrogestone (INN), also known as 6,17α-dimethyl-6-dehydroprogesterone, is a progestational agent derived from 17-methylprogesterone. … It was conceived as an alternative for an orally effective contraceptive option.[A31526] It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing.
Bendazac
go.drugbank.com/drugs/DB13501ApprovedWithdrawna small handful of regions may continue to have the medication available for purchase and use either as a topical anti-inflammatory/analgesic cream or eye drop formulation. … Bendazac is an oxyacetic acid [A39863, A39869].
Ritlecitinib
go.drugbank.com/drugs/DB14924ApprovedInvestigational[A260122,A260127] Other kinases have a cysteine at a position equivalent to Cys-909 in JAK3, and several of them belong to the TEC kinase family. … Ritlecitinib (PF-06651600) is a highly selective inhibitor of Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family.
Levamlodipine
go.drugbank.com/drugs/DB09237ApprovedInvestigationalLevamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. … [A188940] Levamlodipine was granted FDA approval on 19 December 2019.[L10833]
Vigabatrin
go.drugbank.com/drugs/DB01080ApprovedInvestigationalAlthough administered as a racemic mixture, only the S(+) enantiomer is pharmacologically active. … [A202124] Its use is now generally reserved for patients who have failed alternative therapies, and its US approval by the FDA in 2009 mandated the creation of a drug registry to monitor patients for visual
Abrocitinib
go.drugbank.com/drugs/DB14973ApprovedInvestigational[L39774] The Janus kinase (JAK)–signal transducer and activator of transcription (STAT) signalling pathway plays a central role in the pathogenesis of a variety of autoimmune and inflammatory diseases, … including atopic dermatitis, a chronic inflammatory skin disease with complex pathogenesis.
Lisocabtagene maraleucel
go.drugbank.com/drugs/DB16582ApprovedInvestigational[A228493] Despite the adverse reactions, the majority of patients given lisocabtagene maraleucel reported an overall increase in quality of life over a 1 year period. … [A228493] Lisocabtagene maraleucel was granted FDA approval on 5 February 2021 [L31583] and EC approval on 5 April 2022.[L42210] It was later granted Health Canada approval on 6 May 2022.